title: Endoscopic retrograde cholangiopancreatography in the diagnosis and management of cholangiocarcinoma.
abstract: Cholangiocarcinomas (CCAs) are rare malignancies that arise from the biliary epithelium. Intrahepatic CCAs usually present as mass lesions that are asymptomatic or cause nonspecific systemic symptoms such as fatigue, fever, and weight loss. Hilar and extrahepatic tumors most commonly present with jaundice, though cholangitis also can be seen. Tumor markers such as carbohydrate antigen 19-9 and carcinoembryonic antigen have been used to diagnose CCA, but these are nonspecific and may be elevated in infection, inflammation, or any obstruction. Endoscopic retrograde cholangiopancreatography (ERCP) has been used for the diagnosis and management of CCA for many years. This article summarizes the data regarding the application of ERCP in the diagnosis and management of CCA.
authors.affiliation: Mayo Clinic Rochester, MN 55905, USA.
authors.forename: Nayantara
authors.initials: N
authors.lastname: Coelho-Prabhu
authors.forename: Todd H
authors.initials: TH
authors.lastname: Baron
mesh_terms: D000818:Animals; D001650:Bile Duct Neoplasms / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D001653:Bile Ducts, Intrahepatic / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood; D001918:Brachytherapy / Q000009:adverse effects; D018281:Cholangiocarcinoma / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects / Q000379:methods; D000075202:Contraindications; D004322:Drainage; D006801:Humans; D010166:Palliative Care / Q000379:methods; D010778:Photochemotherapy / Q000009:adverse effects; D015607:Stents / Q000009:adverse effects
chemical_list: D014408:Biomarkers, Tumor